Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog
| Autor: | P. Tassi, P. Ormas, G. De Natale, L. Ceci, Chiara Belloli, S. Carli, M. Madonna, G.O. Marcotrigiano |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Antimony
Male Metabolic Clearance Rate Injections Subcutaneous Meglumine antimoniate Biological Availability Pharmacology Injections Intramuscular Dogs Meglumine Pharmacokinetics N methylglucamine Metabolic clearance rate Organometallic Compounds medicine Animals Meglumine Antimoniate General Veterinary business.industry Half-life Bioavailability Anesthesia Injections Intravenous Female business Half-Life medicine.drug Biological availability |
| Zdroj: | Research in Veterinary Science. 56:144-150 |
| ISSN: | 0034-5288 |
| DOI: | 10.1016/0034-5288(94)90096-5 |
| Popis: | The pharmacokinetic profile of antimony in dogs was defined by administering it intravenously, intramuscularly and subcutaneously as N-methylglucamine antimoniate at a dose of about 25.65 mg of antimony kg-1 bodyweight. The results showed a different half-life for the three routes of administration: 20.5, 42.1 and 121.6 minutes for the intravenous, intramuscular and subcutaneous routes, respectively; peak time values (Tmax) were also different for the intramuscular (90 to 120 minutes) and subcutaneous (210 to 240 minutes) injection. The apparent bioavailability of antimony was > 100 per cent for the intramuscular and 100 per cent for the subcutaneous routes. The data obtained showed a relevant difference in the behaviour of the drug in the dog in comparison to that in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|